Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple myeloma.
Richardson PG et al. Blood. 2014 Jun 11. pii: blood-2014-01-548826. [Epub ahead of print].
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Srkalovic G et al. Cancer Med. 2014 Jun 10. doi: 10.1002/cam4.276. [Epub ahead of print].
Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: results from a phase 1 study.
Kumar SK et al. Blood. 2014 Jun 5. pii: blood-2014-01-548941. [Epub ahead of print].
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Patnaik A et al. Br J Cancer. 2014 Jun 5. doi: 10.1038/bjc.2014.290. [Epub ahead of print].
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S et al. Expert Opin Investig Drugs. 2014 Jun 6:1-17. [Epub ahead of print].
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed or refractory multiple myeloma.
Lendvai N et al. Blood. 2014 Jun 24. pii: blood-2014-02-556308. [Epub ahead of print].
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
San-Miguel J et al. Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Epub 2014 May 15